A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer Under the Supervision of Dermatologist and Pediatrician

Burt's Bees Inc.1 site in 1 country20 target enrollmentSeptember 27, 2018

ConditionsAtopic Dermatitis

Overview

Phase: N/A
Intervention: Not specified
Conditions: Atopic Dermatitis
Sponsor: Burt's Bees Inc.
Enrollment: 20
Locations: 1
Primary Endpoint: Eczema Area Severity Index (EASI)
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer Under the Supervision of Dermatologist and Pediatrician

Detailed Description

This single-center clinical trial is being conducted to demonstrate that the Sponsor's product does not statistically or clinically worsen eczema scores in children aged 6 months through 7 years after 4 weeks of treatment compared to baseline scores. Safety and efficacy will be assessed through clinical grading at baseline and week 4. Efficacy will also be assessed through Corneometer and Tewameter measurements at baseline and week 4. Microbiome skin swab sampling will be performed at baseline and week 4. Parents/guardians will complete Patient Oriented Eczema Measure and Family Dermatology Quality of Life Index at baseline and week 4.

Registry

clinicaltrials.gov

Start Date

September 27, 2018

End Date

January 18, 2019

Last Updated

7 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Burt's Bees Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Healthy, female or male infants/children, aged 6 months through 7 years.
•In generally good health (physical, mental, and social well-being, not merely the absence of disease/infirmity), according to parent/legal guardian report.
•Having Fitzpatrick skin type I-VI (refer to Appendix I: Fitzpatrick Skin Type).
•Having mild to moderate eczema involving 3% to 20% of body surface area, and with EASI score in the range of 1.1 to 20.0, further stratified into the following subgroups:
•Approximately 60% of subjects with clinically determined EASI score of 1.1-7.0 (mild)
•Approximately 40% of subjects with clinically determined EASI score of 7.1 to 20.0 (moderate)
•Having a parent/legal guardian at least 18 years of age who regularly bathes the child and otherwise cares for the child, and who presents proof of guardianship (eg, insurance card, certificate of residence, or copy of officially issued family registration) at the baseline visit.
•Having a parent/legal guardian willing to provide written informed consent and who can read, speak, write, and understand English.
•Whose parent/legal guardian is willing to sign a photography release.
•Willing, and having a parent/legal guardian who is willing, to cooperate and participate by following study requirements (including those outlined in section 7.3) for the duration of the study and to report any changes in health status or medications, AE symptoms, or reactions immediately.

Exclusion Criteria

•Diagnosed with known allergies to skin care products or ingredient(s) in the test product.
•History of skin cancer within the past 5 years.
•Individuals who have clinically active bacterial, fungal, or viral skin infections or those who have a history of recurrent cutaneous infections, according to subject self-report.
•Individuals whose use of topical corticosteroids or systemic medications for their eczema has not been stable for at least 6 weeks prior to study start. This includes medicines such as hydrocortisone, clobetasol, betamethasone, halobetasol, fluocinide, diflorasone, mometasone, halcinonide, desoximetasone, pimecrolimus, tacrolimus, crisabarole, and fluticasone.
•Having a health condition and/or pre-existing or dormant dermatologic disease on the body (eg, psoriasis, rosacea, acne \[severe acne, acne conglobata, nodules, or cysts\], seborrheic dermatitis, severe excoriations.) that the Investigator or designee deems inappropriate for participation or could interfere with the outcome of the study.
•Who have observable suntan, scars, nevi, excessive hair, tattoos, or other dermal conditions on the body that might influence the test results in the opinion of the Investigator or designee.
•Having a history of immunosuppression/immune deficiency disorders (including HIV infection, AIDS, multiple sclerosis, Crohn's disease, rheumatoid arthritis), had an organ transplant (heart, kidney, etc), or currently using oral or systemic immunosuppressive medications and biologics that are not used for the treatment of eczema (eg, azathioprine, belimumab, Cimzia, Cosentyx, cyclophosphamide, cyclosporine, Enbrel, Humira, Imuran, Kineret, mycophenolate mofetil, methotrexate, Orencia, Remicade, Rituxan, Siliq, Simponi, Stelara, Taltz) and/or undergoing radiation or chemotherapy as determined by study documentation.
•Having a disease such as asthma, diabetes, epilepsy, hypertension, hyperthyroidism, or hypothyroidism that is not controlled by diet or medication; experiencing asthma flares or having multiple health conditions.
•Having started a long-term medication within the last 2 months.
•With any planned surgeries and/or invasive medical procedures during the course of the study. Non-invasive planned surgeries will be reviewed for their impact on the study outcome and acceptability by the Investigator or designee.

Outcomes

Primary Outcomes

Eczema Area Severity Index (EASI)

Time Frame: 4 Weeks

The primary efficacy endpoint is no worsening of the clinical appearance of atopic dermatitis/eczema as measured by the Eczema Area Severity Index (EASI) at week 4 from baseline. ranges from 0 (no eczema) to 72.

Secondary Outcomes

The secondary endpoint is that the sponsors test materials will be well tolerated and well perceived by subject parents/guardians according to the Family Dermatology Quality of Life Index (FDQLI)(4 Weeks)